Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
O15294
UPID:
OGT1_HUMAN
Alternative names:
O-GlcNAc transferase subunit p110; O-linked N-acetylglucosamine transferase 110 kDa subunit
Alternative UPACC:
O15294; Q7Z3K0; Q8WWM8; Q96CC1; Q9UG57
Background:
The UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunit, also known as O-GlcNAc transferase subunit p110, plays a pivotal role in cellular processes by catalyzing the transfer of N-acetylglucosamine to serine or threonine residues on proteins. This modification affects a wide array of proteins, including histone H2B and insulin signaling components, thereby influencing gene expression, insulin resistance, and glycolysis.
Therapeutic significance:
Given its involvement in Intellectual developmental disorder, X-linked 106, and its role in insulin resistance and cellular signaling pathways, targeting the O-GlcNAc transferase subunit p110 presents a promising avenue for therapeutic intervention in metabolic disorders and intellectual disabilities.